{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-002724","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.945529+00:00","generated_at":"2026-05-16T10:48:56.739567+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Protagonist updates pipeline; icotrokinra NDA Jul '25, rusfertide NDA Dec '25; Phase 3 UC/CD initiated","bullets":["Icotrokinra (oral IL-23R) NDA for psoriasis filed Jul '25; Phase 3 ICONIC-UC and ICONIC-CD initiated Q4 '25; superiority vs deucravacitinib achieved.","Rusfertide (hepcidin mimetic) NDA for polycythemia vera submitted Dec 29 '25; Phase 3 VERIFY met primary endpoint, p<0.0001.","PN-881 (oral IL-17) Phase 1 started Q4 '25; PN-477sc triple agonist Ph1 initiation mid-'26; PN-8047 oral hepcidin dev candidate nominated Q4 '25.","Up to $630M milestones from J&J plus 6-10% royalties; $200M opt-out payment from Takeda for rusfertide plus additional milestones.","Total potential sales milestones from icotrokinra and rusfertide up to $1.2B."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-002724","json":"https://secwatch.observer/filing/0001104659-26-002724.json","markdown":"https://secwatch.observer/filing/0001104659-26-002724.md","text":"https://secwatch.observer/filing/0001104659-26-002724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926002724/0001104659-26-002724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926002724/tm262863d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:48:56.739567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}